There is an old rule of thumb: If it walks like a duck and quacks like a duck, you stop debating taxonomy and call it a duck. When it comes to measles, we have collectively decided not to do that.

The careful phrasing is everywhere you look. The United States “may lose” its measles elimination status. The country’s standing is “at risk.” A panel “will determine” whether elimination should be held. That conditional tense is doing a lot of work, and I understand the instinct, since no one wants to be the doctor who calls it too early. 

But there is a difference between waiting for certainty and refusing to see what is already on the monitor, and the public messaging has slid from caution into false comfort. At its worst, it reads as crisis PR; a careful softening of news that nobody in charge wants to be the one to deliver.

The definition of measles elimination leaves little room for interpretation, and US scientists helped write it. Measles is considered endemic in a given region once local transmission runs continuously for at least one year (so cases that are imported from international travel don’t count unless that person transmits it to others domestically). A country keeps its elimination status only by interrupting that endemicity for at least a year, and requires surveillance systems that are robust enough to detect the difference. These arespecific thresholds that are set with neighboring countries through the Pan American Health Organization (PAHO), which is the regional branch of the World Health Organization (WHO) in the Americas.

Clearly, the data point to continuous spread

The timeline makes this hard to wave away. The massive outbreak in West Texas began on January 20, 2025, which puts the country well past the one-year mark. Seven months later when that outbreak, which resulted in 762 cases, was declared over, measles cases did not stop so much as the outbreaks relocated to other parts of the state and country.

The strongest evidence that this is continuous spread, rather than reintroduction, comes from the virus itself. In a recentanalysis of more than 1,800 whole-genome sequences, ProPublica traced a distinctive set of mutations from the earliest Texas cases through the Utah outbreak, which began in June 2025, and into at least four other states. 

The strain circulating in Utah last month differs from the original Texas virus by just 12 letters out of nearly 16,000, which is far too close to write off as a coincidence. What this pattern describes is a single family tree rather than a string of unrelated introductions from international travel.

For elimination status, it does not matter where the original case came from. What matters is whether the chain ever broke, and a year of nearly identical sequences across multiple states says it did not. Sequencing cannot completely rule out a stray reintroduction somewhere along the way, but that uncertainty cuts the wrong way for anyone hoping to keep the status, because the burden is to prove transmission was interrupted, and the genetics point the other way. 

The definition of measles elimination leaves little room for interpretation, and US scientists helped write it.

The broader epidemiology offers no rescue either. The country logged 48 measles outbreaks in 2025 and another 30 in the first five-plus months of 2026. For perspective, in the entire decade from 2001 to 2011, the stretch when the country was proving elimination would hold, there were 64 outbreaks total. Back then, roughly 40% of cases arrived from abroad, the signature of a country catching measles from elsewhere rather than growing its own. 

By 2025, the imported share had fallen to 10%, and in early 2026 to 6%, meaning measles transmission is now overwhelmingly homegrown. Two children and an adult died of measles last year in what turned out to be the worst year the country had seen in three decades. This year is on pace to be worse. ByJune 18, the United States had confirmed 2,104 cases, within reach of last year’s record total (2,288) with half the year still ahead.

Surveillance is the other half of the definition of measles elimination, and it has gotten only weaker. State and local departments that are on the ground doing most of the infectious disease tracking and surveillance have lost federal funding and staff just when they need to be investigating more, not less. A public health system that cannot distinguish between endemic transmission and elimination is already failing at its job.

So, measured against the definition the nation signed onto, this walks and quacks like endemic measles.

Alternative conclusions don’t hold up

The hedging rests on a thin claim that the outcome is not yet technically settled. Two paths could still allow the United States to keep the label, but neither holds up under much scrutiny.

1. The first is delay. PAHO had originally set the review meeting for April, and it now sits in November, a postponement requested by US health officials who said they needed more time for genomic analysis. Maybe they do. But the analysis window is fixed at one year from January 20, 2025, somoving the meeting changes when the verdict gets read, not what the virus did during the period under review. It is hard to ignore what the delay also buys: an awkward, internationally visible judgment pushed off the calendar for most of the year and onto the same November stretch as the midterm elections. The extra months buy time to find an imported case US officials can point to (proof the chain broke and restarted, rather than ran straight through) and a chance to save some face if they find one. They do not buy the virus any better behavior.
2. The second is leverage. The country withdrew from the WHO, yet itremains a member of PAHO, the body that actually certifies elimination across the Americas. PAHO is reportedly eager to keep the United States engaged. Where delay buys the time to assemble a genomic argument, leverage lowers the bar for what counts as a convincing one. A body reluctant to rule against a member it wants to keep at the table may accept an ambiguous or contested sequence-based narrative, one in which an imported case supposedly restarted the chain, that a stricter review would reject. That would be a way to keep the label on a technicality. It would not change the fact that measles is circulating freely here. 

Losing the designation does not trigger any official penalty. There are no sanctions, no funding cuts, nothing that flips on the day PAHO rules. It simply files the United States alongside the countries in which measles still circulates freely, an official acknowledgment that the immunization system has cracked. Canada lost its own status last November, with the same non-consequence. 

The damage that actually matters (the ongoing transmission, the hospitalizations, the deaths, and the children who do not get the television-and-chicken-soup version of the illness that the health secretary likes to describe) is here, with or without the label. Guarding the designation does nothing, and the status is not won back quickly. To restore its designation, US officials would have to prove interrupted transmission for a full year. 

2 kinds of harms in pretending otherwise

We are very likely going to lose this status, and pretending otherwise does two kinds of harm. It tells the public the situation is borderline and offers a false sense of hope that this year’s shots can still save the status, and it hands the people responsible for the decline an easy story in which the outcome looks like a bureaucratic surprise rather than the foreseeable result of dismantling the very systems that secured elimination to begin with.

Elimination was never permanent, and it was never the product of luck. It took close to 40 years of school vaccination mandates, of free shots for the children whose families could not afford them, and of leaders willing to say plainly that the vaccines are safe and that people should get them. The country managed it once, which means the status is reclaimable.

But if the only thing people hear is that the loss is permanent and measles is simply back, the person who already doubts the shot has every reason to skip it and treat the disease as a one-and-done, just like the old days. The old days had a body count. The message that moves people is the true one: The status is gone for now, it is winnable back, and every vaccine given is part of winning it. 

If the only thing people hear is that the loss is permanent and measles is simply back, the person who already doubts the shot has every reason to skip it.

What we will not do is reclaim it by winning a procedural argument in November. We get it back the same way we earned it the first time, by pushing vaccination coverage back above the level at which measles simply runs out of people to infect. And by building and maintaining a surveillance system that is worthy of claiming elimination. 

A duck is a duck. The sooner we are willing to say so out loud, the sooner we can get back to the work of turning it into something else.

Dr. Steier is a public health scientist and scientific communicator. She is the founder of Unbiased Science, an organization that uses data visualizations, real-world analogies, and human voice to communicate complex scientific concepts for public understanding via multiple media modalities.

The opinions voiced in CIDRAP Op-Ed pieces are the authors’ own and do not necessarily represent the official position of CIDRAP.